The United Laboratories International Holdings Limited (HKG:3933)
Hong Kong · Delayed Price · Currency is HKD 7.32
-0.11 (-1.41%)
Oct 14, 2026, 4:08 PM HKT
HKG:3933 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,858 | 13,211 | 13,759 | 13,740 | 11,334 | 9,703 | |
Revenue Growth | -15.91% | -3.98% | 0.14% | 21.22% | 16.81% | 10.61% |
Cost of Revenue | 8,148 | 7,697 | 7,677 | 7,405 | 6,365 | 5,492 |
Gross Profit | 3,710 | 5,514 | 6,082 | 6,335 | 4,969 | 4,211 |
Selling, General & Admin | 2,321 | 2,303 | 2,297 | 2,384 | 2,366 | 2,332 |
Research & Development | 861.03 | 921.05 | 890.76 | 757.25 | - | - |
Other Operating Expenses | 19.09 | 50.2 | 36.82 | 21.14 | 603.62 | 494.95 |
Operating Expenses | 3,178 | 3,292 | 3,263 | 3,168 | 2,954 | 2,829 |
Operating Income | 531.29 | 2,222 | 2,819 | 3,167 | 2,015 | 1,382 |
Interest Expense | -93.88 | -69.73 | -34.96 | -66.9 | -81.6 | -60.23 |
Interest & Investment Income | 172.5 | 152.57 | 127.79 | 105.42 | 70.74 | 82.78 |
Earnings From Equity Investments | 0.19 | -0.05 | -0.19 | 0.14 | -0.19 | - |
Currency Exchange Gain (Loss) | -232.5 | -27.74 | 117.82 | -2.95 | -21.68 | 42.67 |
Other Non Operating Income (Expenses) | 181.66 | 199.45 | 220.55 | 107.58 | 98.42 | -226.9 |
EBT Excluding Unusual Items | 559.26 | 2,476 | 3,250 | 3,310 | 2,081 | 1,220 |
Gain (Loss) on Sale of Investments | -3.03 | 79.38 | 66.5 | 72.75 | 17.97 | - |
Gain (Loss) on Sale of Assets | 13.17 | 21.04 | -4.27 | -3.7 | -4.39 | -3.3 |
Asset Writedown | 7.48 | -48.59 | -23.3 | -42.39 | -80.34 | -19.25 |
Other Unusual Items | -3.43 | 0.04 | -0.02 | 7.03 | -7.22 | 5.19 |
Pretax Income | 573.45 | 2,528 | 3,289 | 3,344 | 2,007 | 1,203 |
Income Tax Expense | 41.71 | 446.87 | 631.08 | 643.3 | 425.74 | 213.06 |
Earnings From Continuing Operations | 531.74 | 2,081 | 2,658 | 2,701 | 1,581 | 989.59 |
Minority Interest in Earnings | 7.49 | 4.82 | 1.88 | 0.51 | 0.07 | -1.49 |
Net Income | 539.23 | 2,086 | 2,660 | 2,701 | 1,581 | 988.1 |
Net Income to Common | 539.23 | 2,086 | 2,660 | 2,701 | 1,581 | 988.1 |
Net Income Growth | -82.39% | -21.57% | -1.54% | 70.85% | 60.01% | 40.56% |
Shares Outstanding (Basic) | 1,963 | 1,885 | 1,817 | 1,817 | 1,820 | 1,840 |
Shares Outstanding (Diluted) | 1,963 | 1,885 | 1,817 | 1,817 | 1,820 | 1,840 |
Shares Change | 8.05% | 3.76% | -0.01% | -0.15% | -1.10% | 4.20% |
EPS (Basic) | 0.27 | 1.11 | 1.46 | 1.49 | 0.87 | 0.54 |
EPS (Diluted) | 0.27 | 1.11 | 1.46 | 1.49 | 0.87 | 0.54 |
EPS Growth | -83.70% | -24.41% | -1.53% | 71.11% | 61.80% | 34.90% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 222.62 | 947.32 | 1,484 | 1,165 | 1,251 | 1,060 |
Free Cash Flow Per Share | 0.11 | 0.50 | 0.82 | 0.64 | 0.69 | 0.58 |
Dividend Per Share | 0.260 | 0.420 | 0.440 | 0.400 | 0.190 | 0.120 |
Dividend Growth | -40.91% | -4.54% | 10.00% | 110.53% | 58.33% | 50.00% |
Gross Margin | 31.28% | 41.74% | 44.21% | 46.11% | 43.84% | 43.40% |
Operating Margin | 4.48% | 16.82% | 20.49% | 23.05% | 17.78% | 14.24% |
Profit Margin | 4.55% | 15.79% | 19.33% | 19.66% | 13.95% | 10.18% |
Free Cash Flow Margin | 1.88% | 7.17% | 10.79% | 8.48% | 11.04% | 10.93% |
EBITDA | 1,236 | 2,835 | 3,401 | 3,705 | 2,539 | 1,978 |
EBITDA Margin | 10.42% | 21.46% | 24.71% | 26.97% | 22.40% | 20.38% |
D&A For EBITDA | 704.63 | 613.21 | 581.59 | 538.01 | 523.67 | 596.06 |
EBIT | 531.29 | 2,222 | 2,819 | 3,167 | 2,015 | 1,382 |
EBIT Margin | 4.48% | 16.82% | 20.49% | 23.05% | 17.78% | 14.24% |
Effective Tax Rate | 7.27% | 17.68% | 19.19% | 19.24% | 21.21% | 17.72% |